Latest / The Demographics Podcast with Fexingo: Aging Populations, Birth Rates, and Economic Impact / How Falling Birth Rates Are Reshaping the Pharmaceutical Industry
Transcript
- Lucas: There's a number I've been sitting on that really captures how demographic change is quietly reshaping the pharmaceutical industry. According to a report from IQVIA, pediatric prescriptions in the United States have dropped by about 15 percent over the past ten years. Luna: Fifteen percent — that's not a blip. That's a structural shift. Lucas: Exactly. And it maps almost perfectly onto the decline in birth rates. Fewer kids means fewer prescriptions for asthma inhalers, antibiotics, ADHD meds, even baby vaccines, though vaccines tend to be more stable due to mandates. But the overall volume is shrinking. Luna: So what are the big pharma companies doing about it? Are they just accepting the loss? Lucas: Not at all. They're pivoting hard toward geriatric conditions. Think about it: the fastest-growing demographic in most developed countries is people over sixty-five. That population has very different drug needs — cardiovascular, metabolic, neurodegenerative. And those drugs often carry higher price tags and longer treatment durations. Luna: Right. A child might take amoxicillin for ten days. A sixty-five-year-old might take a statin for thirty years. Lucas: Precisely. And the math works out well for the industry when you're looking at lifetime value per patient. I was looking at Pfizer's R&D pipeline, and they've shifted notable resources from pediatric vaccines — they used to have a big pneumococcal vaccine program for kids — toward adult and elder indications, including a respiratory syncytial virus vaccine for older adults. Luna: That's a direct response to the demographic dividend of an aging population. Lucas: It is. And it's not just Pfizer. Novartis has been reorienting around cardiovascular and oncology, which skew older. Even smaller biotechs are increasingly focused on Alzheimer's and Parkinson's. The share of clinical trials for neurodegenerative diseases has more than doubled in the last decade. Luna: But isn't there a risk here? If everyone piles into geriatric drugs, we could see shortages or underinvestment in pediatric medicines. We've already seen that with some cancer drugs — adult ones get developed faster because the market is bigger. Lucas: That's a real concern. The pediatric drug market is smaller and less profitable, so it's becoming a bit of a niche. Some advocacy groups have been pushing for policy incentives to maintain pediatric R&D. The U.S. already has the Best Pharmaceuticals for Children Act, which offers patent extensions for pediatric studies, but there's debate over whether it's enough. Luna: And what about generics? Does the demographic shift affect them too? Lucas: Absolutely. The generic drug market is a volume business. Lower birth rates mean fewer children needing generics for common childhood illnesses. But on the flip side, the aging population increases demand for generic versions of blood pressure meds, diabetes drugs, and cholesterol-lowering agents. So it's not a uniform decline — it's a rebalancing. Luna: So the industry is effectively being reshaped by demography. Are we also seeing this in drug pricing strategies? Lucas: That's the interesting part. Drugs for chronic conditions in older patients tend to have more stable pricing power because patients stay on them for years. But there's also greater price sensitivity because many elderly patients are on fixed incomes. So companies are navigating a tightrope: they need to recoup R&D costs but can't price themselves out of Medicare formularies. Luna: Which brings us back to the broader theme of this podcast: demographic shifts are not just abstract curves — they determine what medicines get made, at what price, and for whom. Lucas: Exactly. And the numbers are only getting more pronounced. The UN projects that by 2050, one in six people will be over sixty-five. That's up from one in eleven in 2019. The pharmaceutical industry is effectively placing its bets on that future. Luna: One more thing: we've talked about prescription drugs, but what about over-the-counter products? Things like pain relievers, cold medicines — do they see the same shift? Lucas: They do, but it's more nuanced. The OTC market is also seeing a decline in pediatric-focused products — fewer children's cough syrups, fewer teething gels. Meanwhile, products for joint pain, sleep aids, digestive health for older adults are growing. It's a mirror of the prescription side. Luna: And you know, I think this is one of those episodes where if it made a connection for you — maybe helped you see the economy in a slightly clearer light — that's the kind of value we try to deliver every day. Lucas: That's a nice way to put it. And honestly, if walking through the economy with us has made something click, the link is buy me a coffee dot com slash fexingo. The smallest possible ask — just if today was worth a coffee to you. Luna: Yeah, listener support keeps this show ad-free and independent. We appreciate it. Lucas: Anyway, back to the pharma shift. There's another layer here that's less obvious: the impact on clinical trial design. With fewer children, it's becoming harder to recruit pediatric trial participants, which slows down drug development for childhood diseases. Luna: Are we seeing any innovative solutions to that? Lucas: Some companies are turning to global trials — enrolling children in regions with higher birth rates, like parts of Africa or Southeast Asia. That brings its own ethical and logistical challenges, but it's a workaround. Others are using real-world evidence from electronic health records to supplement traditional trials. Luna: So the demographic shift is forcing innovation not just in the drugs themselves, but in how they're tested. Lucas: Exactly. And to tie it all together: the key takeaway is that the pharmaceutical industry is in the middle of a silent pivot. If you look at the top ten drugs by revenue today, most are for chronic adult conditions. Ten years ago, that list included more acute and pediatric drugs. The change is clear. Luna: And it's only going to accelerate as the baby boomer generation ages further and Gen Z has fewer kids. Lucas: Right. So for investors, for policymakers, for anyone in healthcare, understanding this demographic undercurrent is essential. It's not a temporary blip — it's a permanent restructuring of the market. Luna: Lucas, thanks for walking us through that. I think listeners will definitely have a new lens next time they see a drug ad. Lucas: Glad to do it. And for those who want to dig deeper, the IQVIA report is public — search for 'IQVIA pediatric prescriptions 2025'. It's a sobering read. Luna: Thanks for listening to The Demographics Podcast. We'll be back tomorrow with another angle on how changing populations are reshaping the world around us.